News | October 15, 2014

RSNA Receives NIBIB Funding for QIBA Research

RSNA has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering to support research by the Quantitative Imaging Biomarkers Alliance

October 15, 2014 – The Radiological Society of North America (RSNA) has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to support research by the Quantitative Imaging Biomarkers Alliance (QIBA). This marks the fourth consecutive year that NIBIB has funded research groundwork by QIBA, following a 2013 contract for $1.25 million.

Quantitative imaging is the extraction of quantifiable features from medical images for the assessment of normal or the severity, degree of change or status of a disease, injury or chronic condition relative to normal.

Quantitative imaging includes the development, standardization and optimization of anatomical, functional and molecular imaging acquisition protocols, data analyses, display methods and reporting structures. These features permit the validation of accurately and precisely obtained image-derived metrics with anatomically and physiologically relevant parameters, including treatment response and outcome, and the use of such metrics in research and patient care.

QIBA is an initiative organized by RSNA in 2007 to advance quantitative imaging and the use of imaging biomarkers in clinical trials and practice.

QIBA engages researchers, healthcare professionals and industry stakeholders by collaborating to identify needs, barriers and solutions to develop and test consistent, reliable, valid and achievable quantitative imaging results across imaging platforms, clinical sites and time. QIBA also works to accelerate the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.

A portion of the new NIBIB award has been earmarked to support QIBA projects and activities, including development of a Quantitative Imaging Data Warehouse, research to characterize the sources of bias and achievable precision associated with quantitative imaging, and to further develop and test phantoms and digital reference objects.

 

“We are honored and gratified that NIBIB continues to recognize the importance of objective, quantitative results from imaging studies to patient care, and provides ongoing support for QIBA’s foundational work in this effort,” said Daniel C. Sullivan, M.D., QIBA Chair.

 

For more information visit: www.rsna.org

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...